Libman–Sacks endocarditis
Libman–Sacks endocarditis is a form of nonbacterial thrombotic endocarditis (NBTE) that is seen in association with systemic lupus erythematosus (SLE). It was first described by the American pathologists Emanuel Libman and Benjamin Sacks in 1924.
Etiology
The exact cause of Libman–Sacks endocarditis is unknown, but it is closely associated with SLE and antiphospholipid syndrome (APS). It is thought to be due to the formation of autoantibodies in these conditions, which cause damage to the endothelium of the heart valves.
Pathology
Libman–Sacks endocarditis is characterized by the presence of sterile vegetations on the heart valves. These vegetations are composed of fibrin and platelets, and are often associated with underlying valve damage. The mitral valve is the most commonly affected, but any valve can be involved.
Clinical features
Patients with Libman–Sacks endocarditis may be asymptomatic, or they may present with symptoms of heart failure, stroke, or systemic embolism. The condition is often discovered incidentally during echocardiography for other reasons.
Diagnosis
The diagnosis of Libman–Sacks endocarditis is made by echocardiography, which shows the characteristic vegetations on the heart valves. Blood tests may show evidence of SLE or APS.
Treatment
The treatment of Libman–Sacks endocarditis involves managing the underlying SLE or APS. This may include immunosuppressive therapy and anticoagulation. In severe cases, valve replacement surgery may be necessary.
Prognosis
The prognosis of Libman–Sacks endocarditis is variable, and depends on the severity of the valve damage and the underlying SLE or APS. With appropriate treatment, the condition can often be managed effectively.
See also
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99


W8MD Medical Weight Loss, Sleep and Medspa offers physician-supervised medical weight loss programs: NYC medical weight loss Philadelphia medical weight loss
Affordable GLP-1 Weight Loss ShotsAffordable GLP-1 Weight Loss Shots
Budget GLP-1 injections NYC (insurance & self-pay options) Popular treatments:
- Semaglutide starting from $29.99/week
- Tirzepatide starting from $45.00/week
✔ Most insurances accepted for visits ✔ Prior authorization support when eligible
Start your physician weight loss NYC journey today:
📍 NYC: Brooklyn weight loss center 📍 Philadelphia: Philadelphia weight loss center
📞 Call: 718-946-5500 (NYC) | 215-676-2334 (Philadelphia)
Tags: Affordable GLP1 weight loss NYC, Wegovy NYC, Zepbound NYC, Philadelphia medical weight loss
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
